Preclinical News and Research

RSS

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of hGH-CTP, the company's proprietary biobetter version of human growth hormone (hGH).

21 Jul 2010

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AiCuris announced today publication of preclinical data on AIC246, at the International Herpesvirus Workshop in Salt Lake City, Utah, USA from 24 – 29 July 2010. AIC246 is a novel anti-HCMV drug currently in clinical phase 2 testing.

21 Jul 2010

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

The American Health Assistance Foundation (AHAF) today announced a new partnership with BioMed Central's open access journal, Molecular Neurodegeneration (MN) in which the publication will be the official open access journal of AHAF.

21 Jul 2010

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

Archer Biosciences, Inc. announced that the trial of its novel, proprietary drug TPI-287 (an abeotaxane) for the treatment of metastatic melanoma has initiated a third drug-escalation cohort. The primary objective of this study is to determine the safety, tolerability and maximum tolerated dose (MTD) of TPI-287 in combination with temozolomide (TMZ) in adult patients with metastatic melanoma.

20 Jul 2010

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.

20 Jul 2010

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Fero Industries, Inc. is pleased to provide these comments regarding the recent Food and Drug Administration advisory panel recommendation concerning the GlaxoSmithKline PLC diabetes drug Avandia. The FDA advisory panel has recommended that the agency keep diabetes drug Avandia on the U.S. market despite data clearly showing an increased risk of a heart attack and that GSK covered up their own research that first identified the problem.

20 Jul 2010

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

Acorda Therapeutics, Inc. today announced the National Heart, Lung, and Blood Institute has awarded a $1 million Cardiac Translational Research Implementation Program grant to support research on Glial Growth Factor 2, a novel investigational agent for the treatment of patients with heart failure under development at Acorda.

20 Jul 2010

Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer

Oncolytics Biotech Inc. today announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers.

19 Jul 2010

Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

Geron Corporation today announced enrollment of the first patient in a randomized Phase 2 clinical trial of its telomerase inhibitor drug, imetelstat (GRN163L), as maintenance therapy following platinum-based induction therapy for patients with non-small cell lung cancer (NSCLC).

19 Jul 2010

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

JANA Partners LLC today sent Charles River Laboratories International, Inc. a detailed critique of Charles River's revised investor presentation released earlier this week, in which Charles River once again seeks to persuade shareholders of the merits of its proposed acquisition of WuXi PharmaTech (Cayman) Inc..

17 Jul 2010

NEOP receives stockholder approval to increase company shares to 205 milliion

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, announced at its 2010 Annual Meeting of Stockholders that it received the approval of its stockholders to increase the number of authorized shares of the Company from 155 million to 205 million. In addition, stockholders re-elected Neoprobe President and CEO David C. Bupp, and elected for the first time, Brendan A. Ford and Eric K. Rowinsky, M.D. as Directors of the Company for terms ending at the 2013 Annual Meeting. Stockholders also approved the appointment of BDO Seidman, LLP to act as the Company's independent registered public accounting firm for 2010.

17 Jul 2010

Initial sponsors of 2nd International Symposium on MR-guided Focused Ultrasound announced

The Focused Ultrasound Surgery Foundation has announced that eight leading manufacturers are among the initial sponsors of the 2nd International Symposium on MR-guided Focused Ultrasound, scheduled for October 17 through 20 near Washington, D.C.

From Elekta 16 Jul 2010

Study results to help researchers better understand cancer genetics, improve treatment regimens

The largest study to correlate genetics with response to cancer drugs releases its first results today. The researchers behind the study, based at Massachusetts General Hospital Cancer Center and the Wellcome Trust Sanger Institute, describe in this initial dataset the responses of 350 cancer samples to 18 anticancer therapeutics.

16 Jul 2010

i26 hyperimmune egg balances improper immune inflammatory response

Our immune systems are in a constant battle with foreign invaders to keep our bodies healthy. Outside forces like pollution, poor nutrition and new strains of disease keep our immune systems at an overly boosted or inflamed state, which affects energy levels, body and emotional health and overall quality of life. Through inflammatory immune cells, our bodies fight to defend us from this onslaught. Too few of these cells can result in illness, while too many could lead to a high immune response, resulting in heightened inflammation and collateral damage to the body's once-healthy tissues.

16 Jul 2010

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

This week, nearly 4,000 scientists from around the world gathered to report and discuss the latest advances in research on treatments, risk factors, and diagnosis for the health epidemic of the 21st century – Alzheimer's disease – at the Alzheimer's Association's 2010 International Conference on Alzheimer's Disease in Honolulu.

15 Jul 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.

15 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

Activities of TAT fully consolidated into Geron

Geron Corporation today announced that the activities of TA Therapeutics, its joint venture with Hong Kong University of Science and Technology, are being fully consolidated into Geron.

15 Jul 2010

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

Watson Pharmaceuticals, Inc. today announced an exclusive, worldwide licensing agreement with Itero Biopharmaceuticals, Inc., a venture-backed specialty biopharmaceutical company, to develop and commercialize Itero's Recombinant Follicle Stimulating Hormone. The product is currently in preclinical development as a biosimilar molecule for the treatment of female infertility.

15 Jul 2010

Plexxikon announces promising preclinical data of PLX3397

Plexxikon Inc. today announced promising preclinical data from in vivo Alzheimer's Disease studies demonstrating a dramatic reduction in activated microglia in the brains of very old (22 months) 3xTG-AD mice, a triple transgenic model for Alzheimer's Disease. This reduction of activated microglia led to significantly improved learning in the treated group.

15 Jul 2010

Preclinical News and Research

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

AiCuris presents preclinical data on AIC246 anti-HCMV drug at International Herpesvirus Workshop

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

Archer Biosciences initiates third drug-escalation cohort in TPI-287 trial for metastatic melanoma

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Fero Industries provides comments concerning FDA advisory panel recommendation on diabetes drug Avandia

Acorda Therapeutics awarded $1M C-TRIP grant to support research on GGF2

Oncolytics Biotech receives Canadian approval for combination REOLYSIN Phase 3 trial in head, neck cancer

Geron commences enrollment in imetelstat Phase 2 clinical trial for NSCLC

JANA Partners sends detailed critique of Charles River's revised investor presentation on WuXi acquisition

NEOP receives stockholder approval to increase company shares to 205 milliion

Initial sponsors of 2nd International Symposium on MR-guided Focused Ultrasound announced

Study results to help researchers better understand cancer genetics, improve treatment regimens

i26 hyperimmune egg balances improper immune inflammatory response

Scientists gather to discuss latest advances in Alzheimer's disease at AAICAD 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

NIH awards MacroGenics $9.8 million grant for three projects

Activities of TAT fully consolidated into Geron

Watson Pharmaceuticals signs exclusive, worldwide licensing agreement with Itero Biopharmaceuticals

Plexxikon announces promising preclinical data of PLX3397

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News